Utrecht

• FIGO 2018 stage IB2 (>2 cm - ≤4 cm ) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) … Recruiting
  2023-507230-24-00 4 2021-02-17 Cervical cancer
• GROINSS-V III Recruiting
  2023-508722-99-00 4 2020-11-19 Vulvar cancer
• Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus … Recruiting
  2024-512526-28-00 5 2020-10-28 Locally recurrent rectal cancer
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 9 2020-10-05 Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
• Treatment of chronic lymphocytic leukaemia with venetoclax and acalabrutinib in case of return of the disease after previous treatment with … Recruiting
  2023-505449-18-00 4 2020-07-23 Patients with relapsed CLL
• An international trial for children with atypical teratoid/rhabdoid tumours (ATRT) Recruiting
  2022-501456-28-00 5 2020-07-20 atypical teratoid/rhabdoid tumours (ATRT)
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 10 2020-07-13 Acute Lymphoblastic Leukaemia
• Doxapram versus placebo in preterm newborns: An international double blinded multicenter randomized controlled trial Recruiting
  2024-515625-29-00 5 2020-06-16 Apnea of prematurity
• Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study) Recruiting
  2023-506546-23-00 5 2020-05-20 Acute myeloid leukemia
• International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica … Recruiting
  2022-501454-11-00 5 2020-02-05 standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 5 2019-12-05 Stage IV childhood renal tumour with pulmonary +/- non-pulmonary metas
• A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting
  2023-509699-41-00 9 2019-11-22 Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high- … Recruiting
  2024-514409-78-01 9 2019-07-26 relapsed / refractory or progressive high risk malignant disease
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 10 2018-12-21 Defined by parent protocol. The study will enroll all adult and paedia
• A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythemat … Recruiting
  2023-507867-20-00 10 2018-10-04 Lupus Erythematosus, Systemic
• A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Recruiting
  2023-504880-18-00 9 2018-04-18 Neuroblastoma (NBL)
• Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting
  2024-513627-16-01 7 2018-03-28 Colorectal cancer metastatic
• Paediatric Hepatic International Tumour Trial Recruiting
  2024-516110-38-00 5 2018-03-06 Hepatoblastoma and Hepatocellular Carcinoma
• Study to allow access to dabrafenib and/or trametinib for subjects that are benefiting from dabrafenib and/or trametinib treatment in a Nova … Recruiting
  2023-509318-13-00 6 2018-01-15 Multiple indications
• Prospective Randomized Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U) Recruiting
  2024-517236-22-00 5 2017-09-20 Intradural saccular unruptured aneurysm
• CAR T-cell therapy long term follow-up Recruiting
  2023-508128-37-00 5 2017-07-19 All patients who have been treated with Novartis or Penn CAR T-cell th
• Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international r … Recruiting
  2024-516196-32-00 5 2017-01-01 breast cancer

Showing 313–336 of 628 trials